BridgeBio Pharma (BBIO) Interest Expenses (2018 - 2026)

BridgeBio Pharma has disclosed Interest Expenses across 9 years of filings, most recently posting $12.9 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $12.9 million, down 28.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.0 million (down 13.65% YoY), and the FY2025 annual result was $53.1 million, down 41.64% from the prior year.
• Interest Expenses came in at $12.9 million for Q1 2026 at BridgeBio Pharma, up from $11.6 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $37.6 million in Q2 2025 to a low of $11.6 million in Q4 2025.
• The 5-year median for Interest Expenses is $20.3 million (2022), against an average of $20.3 million.
• Across the five-year window, Interest Expenses jumped 108.91% in 2022 and sank 49.1% in 2025, its largest moves.
• BridgeBio Pharma's Interest Expenses stood at $20.0 million in 2022, then advanced by 1.39% to $20.3 million in 2023, then advanced by 6.19% to $21.5 million in 2024, then tumbled by 45.93% to $11.6 million in 2025, then advanced by 11.22% to $12.9 million in 2026.
• The last three Interest Expenses figures came in at $12.9 million (Q1 2026), $11.6 million (Q4 2025), and $11.7 million (Q3 2025), per Business Quant data.